Boldly transforming the lives of individuals with rare neurological diseases
boldvision
Science-driven and patient-focused, our mission is to bring treatments to individuals with rare neurological diseases who have little or no treatment options.
boldscience
Our deep understanding of human genetics and cellular function enables us to translate discoveries into meaningful therapies for rare neurological diseases.
boldcommitment
At Ovid, we seek to understand what matters most to individuals with rare diseases and their families. We are committed to address the challenges they face every day.
investor info
Stock quote
NASDAQ: OVID
$3.77
-1.05
16.04.21 | 16:00 PM EST
Copyright West LLC. Minimum 15 minutes delayed.
recent insights
- Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
- Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
- Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
- Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
boldpeople
Each team member understands the difference between a drug and a medicine—one is a product, the other changes lives—and that's what brings us together as Ovidians.